AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a Phase I study titled A Phase I, Open-label, 2 Part, Fixed Sequence Study to Assess the Effect of Co-administration of Camizestrant (AZD9833) on the Pharmacokinetics of Midazolam Exposure (CYP3A4/5 Substrate) and of Carbamazepine (CYP3A4/5 Inducer) on Camizestrant Exposure in Healthy Post Menopausal Female Participants. The study aims to understand how camizestrant affects the pharmacokinetics of midazolam and how carbamazepine affects camizestrant in healthy post-menopausal women, which is significant for optimizing treatment protocols.
Intervention/Treatment: The study tests the effects of camizestrant, a drug administered orally, on midazolam and carbamazepine. Camizestrant is intended to be used in combination with these drugs to assess potential interactions.
Study Design: This interventional study is non-randomized and follows a sequential intervention model. It is open-label, meaning both researchers and participants know which treatments are being administered. The primary purpose is to evaluate treatment effects.
Study Timeline: The study began on August 27, 2024, with primary completion expected later. The last update was submitted on July 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: This study could influence AstraZeneca’s stock performance by providing insights into the effectiveness of camizestrant, potentially enhancing its market position. Investors should watch for results that could impact AstraZeneca’s competitive stance in the pharmaceutical industry, especially regarding drug interactions and treatment efficacy.
The study is ongoing, with further details available on the ClinicalTrials portal.